Idiopathic Pulmonary Fibrosis Market Forecast to Reach USD 6.88 Billion by 2030, Driven by Aging Populations and Rising Treatment Adoption

Mordor Intelligence has published a new report on the Idiopathic Pulmonary Fibrosis Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The global Idiopathic Pulmonary Fibrosis (IPF) market is projected to grow from USD 4.92 billion in 2025 to USD 6.88 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.95%. Key trends include shifting demographics, regulatory approvals of novel therapies, and rising awareness of IPF's underlying causes.

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to severe respiratory issues and reduced life expectancy. IPF primarily affects individuals in their 60s and 70s and is more prevalent among males. Global estimates indicate around 5 million people are affected annually, with an incidence rate near 12 per 100,000 individuals each year. The disease's insidious nature-often first detected through breathing difficulties-makes early intervention vital.

Report Overview: https://www.mordorintelligence.com/industry-reports/idiopathic-pulmonary-fibrosis?utm_source=openpr

Key Trends

Growing Prevalence Due to Demographics
The global population is aging rapidly. WHO projects that by 2030, one in six people will be over 60. IPF predominantly occurs in older demographics, which is directly boosting its incidence and the need for treatment.

Regulatory Momentum for Core Treatments
Approved antifibrotic agents such as pirfenidone and nintedanib remain the backbone of IPF therapy. Pirfenidone gained widespread approval between 2011 and 2014 across the EU, US, and China.

Surge in Clinical Development and R&D
Increased R&D interest is evident in Phase II and III clinical trials exploring novel compounds. Notable examples include LYT‐100 (deupirfenidone) and PLN‐74809, both targeting fibrosis pathways Shelter collaborations such as one between BenevolentAI and AstraZeneca underscore the strategic push into innovative IPF drugs.

Post-COVID‐19 Impact
The COVID‐19 pandemic highlighted the vulnerability of IPF patients to respiratory illnesses and triggered increased diagnosis and hospital visits This has heightened clinician awareness and reinforced treatment pathways.

Emerging Markets in Asia-Pacific
Asia‐Pacific is expected to see the highest growth, with countries like China and India strengthening IPF diagnosis and treatment. Improving access to specialty care and supportive reimbursement regimes in the region bolster market prospects

Market Segmentation

Here's the Market Segmentation for the Idiopathic Pulmonary Fibrosis (IPF) market, adapted from the Mordor Intelligence report:

By Drug Type

Nintedanib

Pirfenidone

Other Drug Types

By Mode of Action

Antifibrotic Agents

Tyrosine Kinase Inhibitors

Other Modes of Action

By End User

Hospitals and Clinics

Pharmacies

Other End Users

By Region

• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• South America

Explore Our Full Library of Healthcare Industry Research Reports

https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Key Players

The IPF market includes a mix of established pharmaceutical companies and emerging biotech's:

Cipla Inc.

Boehringer Ingelheim International GmbH

F. Hoffmann-La Roche Ltd

FibroGen, Inc.

Horizon Therapeutics plc

Conclusion

The global IPF market stands at a crucial inflection point. With rising IPF diagnoses driven by aging demographics and broader testing post-pandemic, the patient base is increasing. Meanwhile, established drugs maintain steady revenues even as generic competition gains ground. Ongoing clinical trials for next-generation agents could shift treatment patterns over the next few years. Regional disparities also present varied opportunities; North America will remain dominant, but Asia-Pacific is poised to expand rapidly.

The outlook for 2025-2030 supports strong market growth. General awareness campaigns, increased funding for IPF research, and hospital-led prescription access all contribute to steady gains. The anticipated market value of USD 6.88 billion by 2030 demonstrates both continued need and evolving treatment dynamics.

Read More: https://www.mordorintelligence.com/ja/industry-reports/idiopathic-pulmonary-fibrosis?utm_source=openpr

Industry Related Reports

Fibrotic Disease Treatment Market: The Fibrotic Disease Treatment Market report is segmented based on treatment type, application, end user, and geography. By treatment, the market includes medication, organ transplantation, oxygen therapy, and other approaches. In terms of application, the market covers idiopathic pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and other fibrotic conditions. The market is further categorized by end user, comprising hospitals, academic and research institutes, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Get More Insights: https://www.mordorintelligence.com/industry-reports/fibrotic-disease-treatment-market?utm_source=openpr

In Silico Protein Design Market: The In Silico Protein Design Market report is segmented by technology type, application, end-user, and geography. By technology type, the market includes molecular modelling and other related technologies. In terms of application, it covers areas such as drug discovery and development, among others. The end-user segment comprises pharmaceutical and biotechnology companies, along with other organizations involved in protein research and development. Geographically, the market is analyzed across regions including North America and other key global markets.

Get More insights: https://www.mordorintelligence.com/industry-reports/in-silico-protein-design-market?utm_source=openpr

Pulmonary Drugs Market: The Pulmonary Drugs Market report is segmented by drug class, mode of delivery, indication, route of administration, distribution channel, and geography. The drug class segment includes beta-2 agonists and other classes. The mode of delivery comprises cloud-based and additional delivery methods. Indications covered in the market include asthma, chronic obstructive pulmonary disease (COPD), and others. The route of administration is categorized into inhaled, oral, and other forms. Distribution channels include hospital pharmacies and other outlets. Geographically, the market is studied across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Market forecasts are presented in terms of value (USD).

Get More Insights: https://www.mordorintelligence.com/industry-reports/pulmonary-drugs-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.